Potential role of PKC inhibitors in the treatment of hematological malignancies

Current Pharmaceutical Design

Volumn 14, Issue 21, 2008, Pages 2075-2084

  Mischiati, Carlo ^a   Melloni, Elisabetta ^b   Corallini, Federica ^b   Milani, Daniela ^b   Bergamini, Carlo ^a   Vaccarezza, Mauro ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

Author keywords

Apoptosis; Hematological malignancies; PKC; Tumorigenesis

Indexed keywords

AMMONIUM TRICHLORO(DIOXYETHYLENE O,O')TELLURATE; BORTEZOMIB; BRYOSTATIN; BUFALIN; CD20 ANTIGEN; COUMARIN DERIVATIVE; CURCUMIN; DECURSIN; DEHYDRODIDEMNIN B; DITERPENE; ENZASTAURIN; FLUDARABINE; GINSENOSIDE RH 2; ISOENZYME; MIDOSTAURIN; PCK 412; PENTAACETYLGENIPOSIDE; PEP 005; PEPLIN; PLANT MEDICINAL PRODUCT; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C THETA; RITUXIMAB; TRICHOSANTHIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; YUANHUACINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; B CELL LYMPHOMA; CALCIUM CELL LEVEL; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LEWIS CARCINOMA; LYMPHATIC LEUKEMIA; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RECOMMENDED DRUG DOSE; SHORT SURVEY;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEMATOLOGIC NEOPLASMS; HUMANS; ISOENZYMES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 52949098335     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208785294618     Document Type: Short Survey

References (125)

1. Berenblum I. The mechanism of carcinogenesis: a study of the significance of carcinogenic action and related phenomena. Cancer Res 1941; 1: 807-14.
2. Castagna M, Takai Y, Kaibuchi K Sano K, Kikkawa U, Nishizuka Y. Direct activation of calpium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-51.
3. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-8.
4. Sharkey NA, Leach KL, Blimberg PM. Competitive inhibition by diacylglycerol of specific phorbol ester binding. Proc Natl Acad Sci USA 1984; 81: 607-10.
5. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-294.
6. Mackay HJ, Twelves CJ, Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007; 7: 554-62.
7. Zauli G, Bassini A, Vitale M, Gibellini D, Celeghini C, Caramelli E, et al. Thrombopoietin enhances the alpha II beta 3-dependent adhesion of megakaryocytic cells to fibrinogen or fibronectin through PI 3 kinase. Blood 1991; 89: 883-95.
8. 133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 1998; 160: 3891-8.
9. Rossi F, McNagny KM, Smith G, Frampton J, Graf T. Lineage commitment of transformed haemopoietic progenitors is determined by the level of PKC activity. EMBO J 1996; 15: 1894-901.
10. Zauli G, Visani G, Bassini A, Caramelli E, Ottaviani E, Bertolaso L, et al. Nuclear translocation of protein kinase C-alpha and -zeta isoforms in HL-60 cells induced to differentiate along the granulo-cytic lineage by all-trans retinoic acid. Br J Haematol 1996; 93: 542-50.
11. Bassini A, Zauli G, Migliaccio G, Migliaccio AR, Pascuccio M, Pierpaoli S, et al. Lineage-restricted expression of protein kinase C isoforms in hematopoiesis. Blood 1999; 93: 1178-88.
12. Mirandola P, Gobbi G, Ponti C, Sponzilli I, Cocco L, Vitale M. PKCepsilon controls protection against TRAIL in erythroid progenitors. Blood 2006; 107: 508-13.
13. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 1995; 9: 484-96.
14. Nishizuka Y. Studies and perspectives of protein kinase C. Science 1986; 233: 305-12.
15. Nishizuka Y. The Albert Lasker Medical Awards. The family of protein kinase C for signal transduction. JAMA 1989; 262: 1826-33.
16. Asaoka Y, Nakamura S, Yoshida K, Nishizuka Y. Protein kinase C, calcium and phospholipid degradation. Trends Biochem Sci 1992; 17: 414-7.
17. Dekker LV, Parker PJ. Protein kinase C - a question of specificity, Trends Biochem Sci 1994; 19: 73-7.
18. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9: 161-7.
19. Gamard CJ, Blobe GC, Hannun YA, Obeid LM. Specific role for protein kinase C-beta in cell differentiation. Cell Growth Differ 1994; 5: 405-9.
20. Borgatti P, Mazzoni M, Carini C, Neri LM, Marchisio M, Bertolaso L, et al. Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation. Exp Cell Res 1996; 224: 72-8.
21. O'Brian C, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49: 3215-7.
22. Schwarts GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 1993; 85: 402-7.
23. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C-beta II is an early promotive event in colon carcinogenesis. Cancer Res 2001; 61: 1375-81.
24. Da Rocha AB, Mans DR, Regner A, Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002; 7: 17-33.
25. Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C- alpha expression. Cancer Res 1996; 56: 3499-507.
26. Shipp MA, Rosa KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profi ling and supervised machine learning. Nat Med 2002; 8: 68-74.
27. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18; 1377-84.
28. Felli MP, Vacea A, Calce A, Bellavia D, Campese AF, Grillo R, et al. PKC-theta mediates pre-TCR signalling and contributes to Notch3-induced T-cell leukemia. Oncogene 2005; 24: 992-1000.
29. Gorelick G, Barreiro Arcos ML, Klecha AJ, Cremaschi GA. Differential expression of protein kinase C isoenzymes related to high nitric oxide synthase activity in a T lymphoma cell line. Biochim Biophys Acta 2002; 1588: 179-88.
30. Villalba M, Kasibhatla S, Genestier L, Mahboubi A, Green DR, Altman A. Protein kinase C-theta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. J Immunol 1999; 163: 5813-9.
31. Parant MR, Klein B, Vial H. Abnormal behavior of protein kinase C in the human myeloma cell line, RPMI 8226. FEBS Lett 1990; 269: 331-5.
32. Thabard W, Collette M, Bataille R, Amiot M. Protein kinase C delta and eta isoenzymes control the shedding of the interleukin 6 receptor alpha in myeloma cells. Biochem J 2001; 358: 193-200.
33. Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta-1 integrin- and phosphatidylinositol 3-kinase-dependent PKC-alpha activation. J Biol Chem 2002; 277: 7875-81.
34. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, et al. Wnts induce migration and invasion of mycloma plasma cells. Blood 2005; 106: 1786-93.
35. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383-95.
36. Chauhan D, Pandey P, Ogata A, Teoh G, Krett N, Halgren R, et al. Cytochrome C-dependent and -independent induction of apoptosis in multiple mycloma cells. J Biol Chem 1997; 272: 29995-7.
37. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
38. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HC1). Blood 2007; 109: 1669-77.
39. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
40. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-26.
41. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999; 18: 2221-30.
42. Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, et al. Protein kinase C lies on the signalling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 1999; 59: 4413-8.
43. Suzuma K, Takahara N, Suzuma. I, Isshiki K, Ucki K, Leitges M, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002; 99: 721-6.
44. Wong C, Jin ZG. Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J Biol Chem 2005; 280: 33262-9.
45. Sledge GW Jr, Gokmen-Polar Y: Protein kinase C beta as a therapeutic target in breast cancer. Semin Oncol 2006; 33: S15-8.
46. Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase C-alpha inhibitor in human bepatocellular and gastric cancer xenografts. In Vivo 2001; 15: 185-93.
47. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom's macroglobulinemia. Blood 2007; 109: 4964-72.
48. Jackson DN, Foster DA. The enigmatic protein kinase C-delta: complex roles in cell proliferation and survival. FASEB J 2004; 18: 627-36.
49. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, et al. Proteolytic activation of protein kinase C-delta by an ICE-like protease in apoptotic cells. EMBO J 1995; 14: 6148-56.
50. Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, Emoto Y, et al. Proteolytic activation of protein kinase C delta by an ICE/CED 3-like protease induces characteristics of apoptosis. J Exp Med 1996; 184: 2399-404.
51. Bharti A, Kraeft SK, Gounder M, Pandey P, Jin S, Yuan ZM, et al. Inactivation of DNA-dependent protein kinase by protein kinase Cdelta: implications for apoptosis. Mol Cell Biol 1998; 18: 6719-28.
52. Yuan ZM, Utsugisawa T, Ishiko T, Nakada S, Huang Y, Kharbanda S, et al. Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation. Oncogene 1998; 16: 1643-8.
53. Cross T, Griffiths G, Deacon E, Sallis R, Gough M, Watters D, et al. PKC-delta is an apoptotic lamin kinase. Oncogene 2000; 19: 2331-7.
54. Frasch SC, Henson PM, Kailey, JM, Richter DA, Janes MS, Fadok VA, et al. Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J Biol Chem 2000; 275: 23065-73.
55. Ni H, Ergin M, Tibudan SS, Denning MF, Izban KF, Alkan S. Protein kinase C-delta is commonly expressed in multiple myeloma cells and its downregulation by rottlerin causes apoptosis. Br J Haematol 2003; 121: 849-56.
56. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, et al. Protein kinase C-alpha activates RAF-1 by direct phosphorylation. Nature 1993; 364: 249-52.
57. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase C-alpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998; 273: 25436-42.
58. Nakagawa R, Soh JW, Michie AM. Subversion of protein kinase C-alpha signaling in hematopoietic progenitor cells results in the generation of a B-cell chronic lymphocytic leukemia-like population in vivo. Cancer Res 2006; 66: 527-34.
59. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, et al. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268: 6090-6.
60. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C-delta. Blood 2002; 100: 3741-8.
61. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase C-beta-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signalling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-9.
62. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C-beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-9.
63. Goekjian PG, Jirousek MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-40.
64. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004; 53: 133-40.
65. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006; 12: 3408-15.
66. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C-beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-6.
67. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, et al. Enzastaurin (LY317615), a protein kinase C inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783-9.
68. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721-4.
69. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR-alpha-induced myeloproliferative disease. Cancer Cell 2003; 3: 459-69.
70. Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005; 24: 8259-67.
71. www.clinicaltrials.gov, accessed March 18th 2008.
72. Sharkey J, Khong T, Spencer A. PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells. Blood 2007; 109: 1712-9.
73. Bahlis NJ, Miao Y, Koc ON, Lee K, Boise LH, Gerson SL. N - Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells. Leuk Lymphoma 2005; 46: 899-908.
74. Clamp A, Jayson GC. The clinical development of the bryostatins. Anticancer Drugs 2002; 13: 673-83.
75. Smith JB, Smith L, Pettit GR. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun 1985; 132: 939-45.
76. Stone RM, Sariban E, Pettit GR, Kufe DW. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 1988; 72: 208-13.
77. Kraft AS, William F, Pettit GR, Lilly MB. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res 1989; 49: 1287-93.
78. Drexler HG, Gignac SM, Jones RA, Scott CS, Pettit GR, Hoffbrand AV. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 1989; 74: 1747-57.
79. Mohammad RM, Al-katib A, Pettit GR, Sensembrenner LL. Differential effects of bryostatin 1 on human non-Hodgkin B-lymphoma cell lines. Leuk Res 1993; 17: 1-8.
80. Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood 2003; 102: 3016-24.
81. Cragg LH, Andreeff M, Feldman E, Roberts J, Murgo A, Winning M, et al. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosyl-cytosine in patients with refractory acute leukemia. Clin Cancer Res 2002; 8: 2123-33.
82. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 56-62.
83. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Rodriguez DH, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res 2000; 6: 825-8.
84. Zauli G, Secchiero P. The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cyt Growth Fact Rev 2006; 17: 245-57.
85. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 2001; 98: 2220-8.
86. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 2002; 100: 2421-9.
87. Secchiero P, Melloni E, Heikinheimo M, Mannisto S, Di Pietro R, Iacone A, et al. TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. Blood 2004; 103: 517-22.
88. Hayun M, Okun E, Hayun R, Gafter U, Albeck M, Longo DL, et al. Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia 2007; 21:1504-13.
89. Wojciechowski W, Li H, Marshall S, Dell'Agnola C, Espinoza-Delgado I. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms. J Immunol 2005; 174: 7859-68.
90. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res 2006; 12:5809-16.
91. Wendtner CM, Eichhorst BF, Hallek MJ. Advances in chemotherapy for chronic lymphocytic leukemia. Semin Hematol 2004; 41: 224-33.
92. Liu JY, Lin SJ, Lin JK. Inhibitory effects of curcumin on protein kinase C activity induced by 12-O-tetradecanoyl-phorbol-13-acetate in NIH 3T3 cells. Carcinogenesis 1993; 145: 857-61.
93. Mahmmoud YA. Modulation of protein kinase C by curcumin; inhibition and activation switched by calcium ions. Br J Pharmacol 2007; 150: 200-8.
94. Lin JK. Molecular targets of curcumin. Adv Exp Med Biol 2007; 595: 227-43.
95. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65(11): 1631-52.
96. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003; 171: 3863-71.
97. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of NF-kappaB and I-kappa B kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-62.
98. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-80.
99. Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006; 6: 259-70.
100. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 2007; 59: 453-70.
101. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 2004; 44: 97-111.
102. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 1998; 78: 739-744.
103. Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT. Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol 1999; 44: 312-318.
104. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 2002; 86: 1510-1517.
105. Gajate C, An F, Mollinedo F. Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95-and mitochondrial-mediated mechanism. Clin Cancer Res 2003; 9: 1535-45.
106. García-Fernández LF, Losada A, Alcaide V, Alvarez AM, Cuadrado A, González L, et al. Aplidin induces the mitochondrial apoptotic totic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002; 21: 7533-44.
107. Hampson P, Chahal H, Khanim F, Hayden R, Mulder A, Assi LK, et al. PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 2005; 106: 1362-8.
108. Jia WW, Bu X, Philips D, Yan H, Liu G, Chen X, et al. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 2004; 82: 431-7.
109. Kim YS, Kim DS, Kim SI. Ginsenoside Rh2 and Rh3 induce differentiation of HL-60 cells into granulocytes: modulation of protein kinase C isoforms during differentiation by ginsenoside Rh2. Int J Biochem Cell Biol 1998; 30: 327-38.
110. Kim HH, Ahn KS, Han H, Choung SY, Choi SY, Kim IH. Decursin and PDBu: two PKC activators distinctively acting in the megakaryocytic differentiation of K562 human erythroleukemia cells. Leuk Res 2005; 29: 1407-13.
111. Kim HH, Sik Bang S, Seok Choi J, Han H, Kim IH. Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett 2005; 223: 191-201.
112. Lee S, Lee YS, Jung SH, Shin KH, Kim BK, Kang SS. Anti-tumor activities of decursinol angelate and decursin from Angelica gigas. Arch Pharm Res 2003; 26: 727-30.
113. Zhang K, Xu J, Huang X, Wu L, Wen C, Hu Y, et al. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562. Cancer Chemother Pharmacol 2007; 60: 581-7.
114. Li J, Xia X, Nie H, Smith MA, Zhu X. PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562. Biochim Biophys Acta 2007; 1770: 63-70.
115. Peng CH, Tseng TH, Liu JY, Hsieh YH, Huang CN, Hsu SP, et al. Penta-acetyl geniposide-induced C6 glioma cell apoptosis was associated with the activation of protein kinase C-delta. Chem Biol Interact 2004; 147: 287-96.
116. Jing Y, Watabe M, Hashimoto S, Nakajo S, Nakaya K. Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 1994; 14: 1193-8.
117. Tian X, Wang PP, Liu YP, Hou KZ, Jin B, Luo Y, et al. Effect of bufalin-inducing apoptosis on Bcl-2 and PKC in HL-60 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 67-71.
118. Kurosawa M, Tani Y, Nishimura S, Numazawa S, Yoshida T. Distinct PKC isozymes regulate bufalin-induced differentiation and apoptosis in human monocytic cells. Am J Physiol Cell Physiol 2001; 280: C459-64.
119. Zhang DC, Cao CX, Zhang CJ, Zhou BN. Yuanhuacin A is a selective antagonist of phorbol ester receptor in protein kinase C. Sci China B 1993; 36: 803-8.
120. Park BY, Min BS, Ahn KS, Kwon OK, Joung H, Bae KH, et al. Daphnane diterpene esters isolated from flower buds of Daphne genkwa induce apoptosis in human myelocytic HL-60 cells and suppress tumor growth in Lewis lung carcinoma (LLC)-inoculated mouse model. J Ethnopharmacol 2007; 111: 496-503.
121. Irie K, Nakagawa Y, Ohigashi H. Toward the development of new medicinal leads with selectivity for protein kinase C isozymes. Chem Rec 2005; 5: 185-95.
122. Irie K, Nakagawa Y, Ohigashi H. Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes. Curr Pharm Des. 2004; 10: 1371-85.
123. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007; 13(18): 1875-86.
124. Sathornsumetee S, Rich JN. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des 2007; 13(35): 3545-58.
125. Thaimattam R, Banerjee R, Miglani R, Iqbal J. Protein kinase inhibitors: structural insights into selectivity. Curr Pharm Des 2007; 13(27): 2751-65.